Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study

Abstract

Background: To compare the costs and effects of paliperidone extended release (ER), a new pharmaceutical treatment for the management of schizophrenia, with the most frequently prescribed oral treatments in Greece (namely risperidone, olanzapine, quetiapine, aripiprazole and ziprasidone) over a 1-year time period.

The Cost of Relapse in Schizophrenia

“…The literature on economic evaluations yielded 8 de novo estimates of the cost of relapse derived either from publicly available data or expert opinion ranging from $1,895 to $48,847 (2015 PPP$) (table 3) [69][70][71][72][73][74][75][76]. Costs of hospital stay were predominantly estimated from national administrative data [70,71,74,75] or expert opinion [72,73,76] on LOS, in combination with daily reimbursement rates. Assumptions on the total inpatient stay varied from 11d [75] to 111d [70] for admitted patients.…”

“…With the exception of two studies [73,75] inpatient costs were supplemented with estimates of additional resource use generated predominantly from expert opinion. Two studies assumed further day hospital stay following discharge of 8d [72] and 23d [69]. Two studies included accommodation costs following discharge from hospital [69,76], one of which generated the largest overall cost estimate [69].…”

“…Two studies included accommodation costs following discharge from hospital [69,76], one of which generated the largest overall cost estimate [69]. Two publications distinguished costs according to whether or not relapse required hospitalisation [72,74], and one study distinguished costs according to whether relapse occurred during first or second line treatment [73].The time period over which costs were estimated varied from 67 days to 1 year, although the selection of 3 months or 1 year was common. Longer periods were not necessarily associated with higher costs.…”

Strošek In Učinkovitost Zdravljenja Shizofrenije Z Atipičnimi Antipsihotiki V Sloveniji: Raziskava Stroškovne Učinkovitosti / The Cost And Effects Of Atypical Antipsychotic Agents In Patients With Schizophrenia In Slovenia: A Cost Effectiveness Study

“…Unauthenticated Download Date | 5/8/18 3:35 PM učinkovitosti antipsihotikov pogosta (29). Iz raziskave smo izključili vse ostale diagnoze, čeprav je komorbidnost pri shizofreniji velika (30).…”

“…Zaradi pomanjkanja enoletnih študij smo primerjali tudi rezultate šest tedenskih študij, saj smo te lahko najbolj enostavno primerjali prek istih meril. V raziskavo smo pri izračunu končnih učinkovitosti zdravljenja vključili relevantno multicentrično raziskavo CATIE, ki so jo raziskovalci pogosto vključili v študije stroškovne učinkovitosti (29,33). Ob primerjavi učinkovitosti posameznih antipsihotikov v izbranih primerjalnih kratkih študijah in uporabljenih študijah v našem odločitvenem drevesu vidimo podobnosti.…”